KD101

DRUG3 trials

Sponsors

Kwang Dong Pharmaceutical co., ltd., Seoul National University Hospital

Conditions

Drug ToxicityObesity

Phase 1

Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects

CompletedNCT01979380

Kwang Dong Pharmaceutical co., ltd.Drug Toxicity

Start: 2013-12-31End: 2014-08-31Updated: 2014-08-12

To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects

Kwang Dong Pharmaceutical co., ltd.Obesity

Start: 2015-03-31End: 2016-03-31Target: 38Updated: 2015-06-03

A Phase I Study to Investigate the ADME of KD101

CompletedNCT02819934

Seoul National University HospitalObesity

Start: 2016-05-20End: 2018-12-15Updated: 2020-03-19